Top-Line Results for Arena’s IBD Immunomodulator Announced

Top-Line Results for Arena’s IBD Immunomodulator Announced
San Diego, California-based Arena Pharmaceuticals, Inc. has just revealed positive findings from a Phase 1b clinical trial for APD334, an orally administered pipeline immunomodulator that works to lower destructive lymphocytes by targeting the sphingosine 1-phosphate subtype 1 (S1P1) receptor in order to treat autoimmune conditions, such as inflammatory bowel diseases (IBD). The randomized, double-blind, placebo-controlled Phase 1b clinical

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *